# US 9,005,981 B2 · Assays utilizing nicotinic acetylcholine receptor subunits > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,005,981 B2 - Document ID: US9005981B2 - Status: Granted - Kind: B2 - Application number: 12/644,683 - Filed: 2009-12-22 - Published: 2010-08-19 - Granted: 2015-04-14 - Earliest claimed: 2008-12-30 - Assignees: Dow AgroSciences LLC - Applicants: Nailah Orr; Gerald B. Watson; Gary D. Gustafson; James M. Hasler; Chaoxian Geng; Scott Chouinard; Kevin R. Cook; Vincent L. Salgado - Inventors: Nailah Orr; Gerald B. Watson; Gary D. Gustafson; James M. Hasler; Chaoxian Geng; Scott Chouinard; Kevin R. Cook; Vincent L. Salgado - Web page: https://patentgrep.com/patent/US9005981B2 ## CPC - C07K 16/286: {against neuromediator receptors, e.g. serotonin receptor, dopamine receptor} - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C12N 2503/00: Use of cells in diagnostics - C12N 2510/00: Genetically modified cells - G01N 2333/43552: from insects - G01N 2333/70571: for neuromediators, e.g. serotonin receptor, dopamine receptor - G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present invention is in the field of identification and characterization of novel insecticidal target sites and, in particular, relates to host cells, assays and antibodies thereto. ## Claims ### Claim 1 A non-human transgenic organism comprising a heterologous polynucleotide that is at least 99% identical to SEQ ID NO: 15 that encodes a receptor subunit and results in a reduced response of the transgenic organism to a spinosyn, relative to the parental organism that does not comprise the heterologous polynucleotide that is at least 99% identical to SEQ ID NO: 15. ### Claim 2 (depends on 1) The transgenic organism of claim 1, wherein the organism is an invertebrate. ### Claim 3 (depends on 1) The transgenic organism of claim 1, wherein the organism is a fly. ### Claim 4 (depends on 1) The transgenic organism of claim 1, wherein the genome of the organism is homozygous for the mutant gene. ### Claim 5 (depends on 1) The transgenic organism of claim 1, wherein the organism is an insect. ### Claim 6 (depends on 1) The transgenic organism of claim 1, wherein the heterologous polynucleotide that is at least 99% identical to SEQ ID NO: 15 has been introduced into the organism's genome by homologous recombination. ### Claim 7 (depends on 1) The non-human transgenic organism of claim 1, wherein the polynucleotide is SEQ ID NO:15. ### Claim 8 (depends on 7) The transgenic organism of claim 7, wherein the organism is an invertebrate. ### Claim 9 (depends on 7) The transgenic organism of claim 7, wherein the organism is a fly. ### Claim 10 (depends on 7) The transgenic organism of claim 7, wherein the genome of the organism comprises two copies of the polynucleotide. ### Claim 11 (depends on 7) The transgenic organism of claim 7, wherein the heterologous polynucleotide of SEQ ID NO: 15 has been introduced into the organism's genome by homologous recombination. ### Claim 12 A kit for use in screening compounds for activity, the kit comprising: a non-human transgenic organism comprising a heterologous polynucleotide that is at least 99% identical to SEQ ID NO: 15 that encodes a receptor subunit and results in a reduced response of the transgenic organism to a spinosyn, relative to the parental organism that does not comprise the heterologous polynucleotide that is at least 99% identical to SEQ ID NO: 15. ### Claim 13 A method for screening a compound, the method comprising: i) providing a non-human transgenic organism comprising a heterologous polynucleotide that is at least 99% identical to SEQ ID NO: 15 that encodes a receptor subunit and results in a reduced response of the transgenic organism to a spinosyn, relative to the parental organism that does not comprise the heterologous polynucleotide that is at least 99% identical to SEQ ID NO: 15; ii) administering the compound to said non-human transgenic organism of step (i); and iii) observing the effect of the compound on said non-human transgenic organism of step (ii). ### Claim 14 (depends on 13) The method according to claim 13, wherein the transgenic organism is a vertebrate. ### Claim 15 (depends on 13) The method according to claim 13, wherein the transgenic organism is a fish. ### Claim 16 (depends on 13) The method according to claim 13, wherein the transgenic organism is a zebrafish. ### Claim 17 (depends on 13) The method according to claim 13, wherein the transgenic organism is a mouse.